Management of Irregular Heartbeat in AFib/CHF Patient on Optimal Medical Therapy

Initial Assessment and Management

The American Heart Association recommends assessing whether the patient is experiencing symptomatic rapid ventricular response (RVR) or simply perceiving their baseline irregular rhythm, as this distinction determines whether rate control optimization versus reassurance is needed 1
The American College of Cardiology suggests immediately checking critical parameters, including heart rate at rest and during activity, with a target of <100 bpm at rest and <110 bpm during moderate exercise 1
The European Society of Cardiology recommends checking blood pressure and signs of hemodynamic instability, such as hypotension, acute pulmonary edema, and chest pain 1, 2
The American Heart Association recommends checking volume status, looking for signs of decompensated heart failure, such as peripheral edema, elevated JVP, and pulmonary congestion 1
The American College of Cardiology suggests confirming medication adherence, including metoprolol 50mg, as prescribed 1

The American Heart Association recommends optimizing beta-blocker dosing, as metoprolol 50mg may be subtherapeutic, and increasing the dose to 100-200mg daily if tolerated 1
The American College of Cardiology suggests adding digoxin 0.125-0.25mg daily if beta-blocker uptitration is insufficient 1, 2
The European Heart Journal recommends considering amiodarone if rate remains uncontrolled despite beta-blocker and digoxin combination 1

The American Heart Association recommends considering rhythm control with cardioversion and antiarrhythmic therapy if the patient remains symptomatic despite adequate rate control 1, 3
The European Society of Cardiology suggests using amiodarone as the preferred antiarrhythmic for patients with heart failure and reduced ejection fraction 1, 3
The American College of Cardiology recommends avoiding Class IC agents, such as flecainide and propafenone, in patients with structural heart disease 3

The American Heart Association recommends avoiding non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, if the patient has reduced ejection fraction, as these are contraindicated due to negative inotropic effects 1
The American College of Cardiology suggests not using digoxin as monotherapy, as it is ineffective for acute rate control and works primarily at rest, not during activity 2, 4